AI assistant
Humacyte, Inc. — Director's Dealing 2025
Jun 16, 2025
33410_dirs_2025-06-16_74491e93-3f21-42d7-b4a2-44b3047aa523.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2025-06-12
Reporting Person: Dougan Brady W (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-12 | Stock Options (right to buy) | $2.41 | A | 0 | Acquired | 2035-06-12 | Common Stock (80000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 0 | Direct |
| Common Stock | 2241045 | Indirect |
| Common Stock | 243851 | Indirect |
| Common Stock | 1148240 | Indirect |
Footnotes
F1: This Form 4 amends the previously reported number of shares owned by the Reporting Person and Ayabudge LLC, an entity controlled by the Reporting Person, to correct an error in a Form 4 filed by the Reporting Person on August 21, 2023 (the "Original Form 4"). The Original Form 4 reported the sale of 510,161 shares of common stock of Humacyte, Inc. as a sale by Ayabudge LLC; however, these shares were sold by the Reporting Person.
F2: The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029.